抗心磷脂抗体定性定量方法在抗磷脂综合征疗效评价中的应用

目的探讨抗磷脂综合征(APS)患者治疗前后的抗心磷脂抗体(ACA)的定性定量水平及其对妊娠结局的影响,比较ACA定量与定性的准确性和灵敏度。方法对我院门诊APS孕妇40例,用定性定量方法监测治疗前后ACA的变化及对治疗后妊娠结局的影响。结果(1)定量方法检测治疗前的ACA-IgG和ACA-IgM滴度分别为(67.63±2.53)U和(49.40±3.64)U;治疗后的ACA-IgG和ACA-IgM滴度分别为(23.87±1.54)U和(21.60±2.59)U,两者比较,治疗后的ACA滴度水平显著低于治疗前水平(P<0.01)。定性方法检测APS孕妇,治疗后ACA转阴率为75%。(2)40例孕妇经治疗均娩出正常新生儿,ACA定量转阴组的妊娠并发症发生率(0.6%)较未转阴组(14.3%)显著降低(P<0.01)。ACA定性定量同时阴性组的妊娠并发症发生率(0.9%)较定性阴性而定量阳性组(7.1%)显著降低(P<0.05)。(3)治疗后30例孕妇ACA定性转阴,但其ACA-IgG和ACA-IgM滴度分别为(27.63±6.05)和(20.13±5.60)U/ml。结论ACA定性与定量均能准确有效的监测ACA水平,反映疗效及预测预后;ACA定量是一种较定性更准确灵敏的诊断监测方法。     

孕妇配偶的心理压力研究

目的描述孕妇配偶的压力水平 ,找出引起孕妇配偶压力的主要压力源。方法对 167例孕妇配偶用妊娠压力量表测量其压力水平及压力源。结果孕妇配偶的妊娠压力水平总分为 1.5 3 ,引起孕妇配偶压力的最主要的压力源是“为确保母子健康和安全而引发的压力 ( 1.88)”。结论护士的服务对象不应局限于孕妇 ,还应包括其配偶 ,根据孕妇配偶具体的压力源给予有针对性的护理 ,以利于有效地降低其压力水平。使孕妇配偶能顺利地度过角色转变期 ,在妊娠和分娩的应激下保持心身健康 ,更好地完成照顾孕妇和婴儿的任务。     

降调节对卵子质量的影响

近10余年来，在体外受精一胚胎移植（IVF-ET）周期中应用促性腺激素释放激素激动剂（GnRH-a）进行控制性卵巢刺激（COS）已成为普遍采用的方法，其主要原因是GnRH-a可以促进卵巢内多个卵泡同步发育和成熟，抑制内源性黄体生成素（LH）峰，阻遏卵泡过早黄素化及卵子早熟。由于GnRH-a在IVF-ET进行降调节COS中的应用不同，可将COS方案分为长方案和短方案。[第一段]     

输卵管积水处理方式对体外受精-胚胎移植临床结局的影响

目的探讨输卵管积水的不同腹腔镜手术处理方式对体外受精-胚胎移植(IVF-ET)临床结局的影响。方法回顾性分析2006年1月至2007年7月因输卵管因素在本中心行常规IVF-ET治疗的294例不育患者的资料,按IVF-ET前腹腔镜下输卵管积水处理方式分组:A组:双侧输卵管近端结扎术28例;B组:双侧输卵管造口术42例;C组:双侧输卵管切除术64例;D组:输卵管阻塞不伴积水80例;E组:单或双侧输卵管积水80例。比较5组患者在IVF-ET周期中卵巢对超排卵的反应性及临床结局的影响。结果C组的窦卵泡数少于B组,发育的卵泡数及获卵数少于其他4组,均有显著性差异(P<0.05);与其他4组相比,C组使用促性腺激素(Gn)的支数最多,但无显著性差异(P>0.05);E组的胚胎植入率为15.9%,临床妊娠率为27.5%,为各组间最低,其中胚胎植入率与A、C和D组比较有显著性差异,临床妊娠率与A和D组比较有显著性差异(P<0.05);各组流产率E组最高(22.7%),其次为B组(14.4%),E与C组(4%)比较有显著性差异(P<0.05);异位妊娠率E组最高,其次为B组,但各组间无显著性差异(P>0.05)。结论输卵管积水对IVF-ET结局有负面影响,对输卵管积水进行适当预处理有助于改善其临床结局。输卵管近端结扎术不降低卵巢反应性,异位妊娠率及流产率低,是IVF-ET前输卵管积水预处理较理想手术方式。     

腹腔镜下处理输卵管积水对体外受精胚胎移植结局的影响

目的探讨腹腔镜下处理输卵管积水对体外受精胚胎移植(in vitro fertilization and embryo transfer, IVF-ET)结局的影响.方法 2002～2005年在我院行IVF-ET伴输卵管积水的53例分3个研究组:①未处理组17例,仅行IVF-ET,未对积水进行处理;②直接切除组17例,行IVF-ET术前在腹腔镜下处理输卵管积水;③失败后切除组19例,IVF-ET失败后腹腔镜下处理输卵管积水后再行IVF-ET.结果未处理组新鲜移植周期妊娠率15.8%(3/19),解冻周期妊娠率10.5%(2/19),平均周期妊娠率13.2%(5/38),累积活胎率17.6%(3/17);直接切除组分别为36.8%(7/19),23.1%(3/13),30.3%(10/32),41.7%(8/17);失败后切除组分别为16.7%(2/12),58.3%(14/24),44.4%(16/36),73.7%(14/19).失败后切除组的解冻周期妊娠率、平均周期妊娠率及累积活胎率均高于未处理组(χ2＝10.374,P＝0.001;χ2＝8.903,P＝0.003;χ2＝11.305,P＝0.001),直接切除组平均周期妊娠率及累积活胎率呈高于未处理组的趋势(χ2＝3.377,P＝0.066;χ2＝3.360,P＝0.067).结论输卵管积水降低IVF-ET的妊娠率,妊娠结局不良,腹腔镜下处理输卵管积水后再行IVF-ET提高妊娠率,获得良好的妊娠结局.     

Preliminary Report on Teratogenic Effects of Zonisamide in the Offspring of Treated Women with Epilepsy

Summary: Purpose: We wished to assess the risk of terato-genicity of zonisamide (ZNS) in humans.
Methods: Pregnant epileptic women treated with ZNS and their offspring were prospectively monitored from June 1989 to December 1994. The outcome of pregnancy and status of neonates were examined based on the same standardized protocol.
Results: Twenty-six offspring exposed to ZNS with or without other antiepileptic drugs (AEDs) were studied. Malformations were detected in 2 offspring (7·7%) exposed to ZNS polypharmacy. Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septa1 defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section). Serum concentrations of ZNS during the first trimester of pregnancy were 6·1 μg/ml in case 1 and 6·3μ/ml in case 2; in both cases, the levels were below the therapeutic concentration range of ZNS.
Conclusions: Teratogenic effects of ZNS were not clearly defined from these results since malformations were detected in two polypharmacy cases but not in four monopharmacy cases. The present data do not indicate that the risk of ZNS teratogenicity is greater than that of other conventional AEDs. However, such risk cannot be neglected even at therapeutic dosages or concentrations of ZNS, especially in patients receiving polypharmacy.     

Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy

Objective: Routine malaria prophylaxis with chloroquine (CQ) is recommended to pregnant semi-immune women in several countries in Africa. The dosage is empirically based. We investigated whether blood CQ concentrations and apparent oral blood clearance (CL/F) change during the course of pregnancy. We also studied whether malaria parasites could be detected together with low CQ blood levels. Methods: Forty nine semi-immune Tanzanian women were recruited in the 16th week of pregnancy. They were given 310 mg oral CQ base once per week as prophylaxis during the whole pregnancy. Capillary blood samples were taken for analysis of CQ before treatment and at weeks 26 and 36. Blood samples were dried on filter paper and analysed by HPLC. Blood was also drawn to detect occurrence of malaria parasites. Results: A total of 25 women fulfilled the sampling schedule. CL/F increased significantly from 160 ml ·  min⁻¹ at week 26 to 180 ml · min⁻¹ at week 36. In 7 of 25 women, CL/F increased >20%. Trough blood CQ concentrations, determined on four occasions at week 26 and at week 36 varied between 200 and 900 nmol · l⁻¹. No statistically significant differences between occasions were seen. Malaria parasites were seen in two individuals early in pregnancy. Conclusion: Blood CQ CL/F showed a small increase during the course of pregnancy. The estimated mean blood CL/F values of 160 and 180 ml · min⁻¹ (week 26 and 36, respectively) were higher than the mean CL/F of 125 ml · min⁻¹ in non-pregnant individuals, published previously. Efficacy of higher dosages of CQ in malaria prophylaxis in pregnant women could, therefore, be evaluated in controlled trials in high-risk malaria areas. Received: 3 July 1996 / Accepted in revised form: 5 November 1996     

可溶性细胞间粘附分子-1在妊娠期高血压疾病中的作用

目的:探讨可溶性细胞间粘附分子-1在妊娠期高血压疾病患者血浆中的变化,为临床诊治提供依据。方法:用ELISA法检测29例妊娠期高血压疾病患者血浆中可溶性细胞间粘附分子-1水平,并与正常妊娠组和正常对照组进行组间比较。结果:子痫前期组、妊娠期高血压组、正常妊娠组晚期及正常对照组的可溶性细胞间粘附分子-1水平分别为1129.82±399.16、794.35±255.57、661.51±301.79及549.23±139.98ng/ml。组间比较,子痫前期组与妊娠期高血压组之间P<0.05,与正常妊娠组晚期及正常对照组之间P<0.001;妊娠期高血压组与正常对照组之间P<0.001;妊娠期高血压组与正常妊娠组晚期相比P>0.05,正常妊娠组3个不同孕龄阶段P>0.05。结论:可溶性细胞间粘附分子-1在妊娠期高血压疾病时显著升高,并随病情的加重而增高,可作为该病诊断和监控的一项指标。